We aimed to describe treatment patterns of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who progressed after receiving darolutamide in a real-world setting, and according to the standard clinical practice in Spain.
This was a multicenter, observational, retrospective study conducted at the urology and oncology departments of 17 Spanish hospitals that participated in the ARAMIS trial and its rollover study.
85 patients, with a median age of 76 years, were included in the study. 49 patients (57.6%) progressed to mCRPC, with metastases located mainly in bone. Only 35 of them (71.4%) received at least one subsequent therapy. The most common first-line treatments after darolutamide were abiraterone (n = 22, 63%) and docetaxel (n = 10, 29%), with a median (IQR) treatment duration of 7.6 months (4.7, 12.7) and 4.8 months (3.8, 5.8), respectively; besides, the most frequent first-line/second-line treatment sequences were abiraterone-docetaxel and docetaxel-cabazitaxel. In addition, only 20% of patients with bone metastases received osteoclast-targeted therapy.
These real-world practice patterns suggest a lack of consensus in Spanish clinical practice for the management of patients with mCRPC, indicating that there is a need for more standardized strategies and unification of the criteria to make decisions in accordance with the recommendations of international clinical practice guidelines.
Not applicable.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2026 Feb 10 [Epub ahead of print]
Javier Puente, Rubén Campanario, David Marmolejo, Juan Andrés Cantero-Mellado, Álvaro Gómez-Ferrer, Alfredo Rodríguez Antolín, María J Ribal, Natalia Picola Brau, María José Ledo, Carlos Hernandez, Carlos Llorente, Carmen González-Enguita, Álvaro Bisonó Castillo, Joan Benejam, Jesús Gil Guijarro, Jose Garcia-Sanchez, Joan Folqué, Javier Casas-Nebra
Department of Medical Oncology, Hospital Clínico San Carlos, C/Profesor Martin Lagos S/N, 28040, Madrid, Spain. ., Department of Urology, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Department of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Department of Urology, Hospital Clínico Universitario Virgen de La Victoria, Málaga, Spain., Department of Urology, Instituto Valenciano de Oncología, Valencia, Spain., Department of Urology, Hospital Universitario, 12 de Octubre, Madrid, Spain., Uro-Oncology Unit, Hospital Clínic de Barcelona, Barcelona, Spain., Department of Urology, Bellvitge University Hospital, Barcelona, Spain., Department of Urology, Hospital Universitario Puerta del Mar, Cádiz, Spain., Department of Urology, Gregorio Marañón University General Hospital, Madrid, Spain., Department of Urology, Hospital Universitario Fundacion Alcorcon, Alcorcón, Spain., Department of Urology, Hospital Universitario Fundación Jiménez Díaz, UAM, Madrid, Spain., Hospital Universitario de Jerez de la Frontera, Jerez De La Frontera, Spain., Department of Urology, Hospital de Manacor, Mallorca, Spain., Department of Urology, Hospital General Universitario de Elche, Elche, Spain., Department of Oncology, Hospital Arnau de Vilanova, Valencia, Spain., Bayer Hispania, S.L., Sant Joan Despí (Barcelona), Spain., Department of Urology, Hospital Universitario Lucus Augusti, Lugo, Spain.